A Faster Diagnostic Test. What Changes for the Patient?

Also published on LinkedIn.

A diagnostic test result can arrive earlier without changing when a patient receives treatment, moves to another service or goes home.

That possibility deserves attention when a new diagnostic technology is introduced. Faster information may be valuable, but the intended benefit depends on a sequence of decisions and actions around it. Someone needs to receive the result, interpret it in context and have the authority and resources to act.

For leaders developing, adopting or scaling diagnostic technologies, the practical question is: which part of the patient’s care will change because this information is available?

England’s introduction of newborn screening for spinal muscular atrophy (SMA) makes those dependencies visible. SMA is a rare inherited condition affecting the nerves that control muscles. Screening uses the routine newborn blood-spot sample collected through a heel prick to identify babies who may have the condition. Screening and diagnosis serve different purposes: a result suggesting SMA requires confirmatory testing and specialist assessment before a diagnosis is established. Government FAQs.

The in-service evaluation began in the West Midlands on 1 October 2026. Introduction is phased, with findings intended to inform a future recommendation on whether and how screening should continue. UK National Screening Committee.

The published arrangements explicitly connect screening with urgent specialist assessment, confirmatory testing and consideration of appropriate treatment and ongoing care. They are not evidence of a neglected or failing pathway. They illustrate why introducing screening involves responsibilities extending beyond the laboratory. RJAH.

The care pathway is that connected sequence: from identifying a need for testing through investigation, clinical decisions and subsequent care. Its effectiveness depends on how the steps work together.

A similar strategic question arises with point-of-care diagnostic testing—testing performed at or near the place where a patient receives care—and with rapid diagnostic tests used in emergency departments.

These settings differ substantially from screening newborns before symptoms appear. The urgency, patient populations and decisions are different. The useful comparison concerns the relationship between receiving information and being able to use it.

An emergency-department diagnostic test intended to support an admission or discharge decision needs to fit the timing of that decision. A result intended to influence treatment needs to reach the clinician while the choice remains open, or trigger a clearly assigned review afterward.

The ResPOC randomized trial provides a concrete example. Published in 2017, it studied rapid molecular testing for respiratory viruses in adults presenting to a UK emergency department or acute medical unit. Testing did not reduce the overall proportion receiving antibiotics, although several secondary outcomes improved, including appropriate antiviral treatment and mean hospital length of stay. The authors noted that many patients had already started antibiotics before results became available. Brendish and colleagues, The Lancet Respiratory Medicine.

The study does not establish that all rapid diagnostic testing needs the same workflow, or that pathway planning alone determines outcomes. It does illustrate why a test can affect different decisions differently. A result arriving too late to influence initial prescribing may still support a subsequent treatment review.

This is where adoption planning needs practical depth.

Before introducing a diagnostic test, the intended change in care should be explicit.

Earlier confirmation of a diagnosis, more appropriate treatment, earlier discharge and better use of isolation facilities are different objectives. Each depends on different people, information and resources.

Consider a hypothetical emergency-department service introducing a faster diagnostic test to support earlier discharge. If the result becomes available sooner but the patient still needs imaging or specialist review, testing may no longer be the step determining departure time. Diagnostic uncertainty may have been reduced, which can matter clinically, while the expected reduction in time spent in the department remains unrealized.

That distinction should shape the business case. Time saved in producing a result cannot automatically be counted as time saved for the patient or capacity released for the hospital.

Planning also needs to start before the sample reaches the instrument. Who identifies eligible patients? When is the test ordered? Who collects the sample and operates the system? A short analytical turnaround time may have limited influence if testing starts late in the assessment.

Afterward, responsibility needs to extend beyond making the result available. Who receives it during a busy shift? Who reviews it if the patient has moved to another team? What happens when it is inconclusive or requires confirmation?

These questions should lead to agreed responsibilities, staffing and escalation arrangements. A pathway diagram is useful only if the people expected to deliver it can do so.

The economics deserve the same scrutiny. Bringing diagnostic testing closer to patients can change who performs the work and which department carries its cost. A service investing in testing may depend on another service to deliver the anticipated benefit. Those commitments belong in the adoption plan, particularly when budgets and management responsibilities are separate.

For diagnostic companies, this has direct commercial implications. Understanding the customer’s intended clinical use should influence implementation support, partnerships, customer selection and growth forecasts. A supplier can support that work without claiming ownership of clinical decisions or promising outcomes that depend on resources beyond its control.

Complete certainty is neither realistic nor a prerequisite for adoption. Some requirements will become clearer through use. Leaders can still identify the major dependencies upfront, assign responsibility for them and review whether the expected changes in care are occurring.

Measurement should connect the performance of diagnostic testing with the intended patient-care decision. Depending on the use case, that might include time to appropriate treatment, completion of confirmatory assessment or a safe discharge decision. These measures also need clinical outcomes and safety checks; faster decisions alone do not establish better care.

The lesson from newborn SMA screening and acute-care diagnostics is a shared planning responsibility, despite their different clinical purposes. When an investment promises to change patient care, its plan should name the decision being changed, the people responsible and the capacity needed to carry it through.